Norges Bank Purchases Shares of 699,641 Maximus, Inc. $MMS

Norges Bank purchased a new stake in Maximus, Inc. (NYSE:MMS) during the fourth quarter, Holdings Channel.com reports. The institutional investor purchased 699,641 shares of the health services provider’s stock, valued at approximately $60,393,000.

A number of other institutional investors have also recently made changes to their positions in the stock. Dimensional Fund Advisors LP grew its position in shares of Maximus by 2.0% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,869,573 shares of the health services provider’s stock valued at $170,812,000 after buying an additional 36,989 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Maximus by 0.3% in the 4th quarter. Geode Capital Management LLC now owns 1,482,079 shares of the health services provider’s stock valued at $127,952,000 after buying an additional 5,130 shares during the last quarter. Boston Partners grew its position in shares of Maximus by 47.0% in the 3rd quarter. Boston Partners now owns 966,139 shares of the health services provider’s stock valued at $88,236,000 after buying an additional 308,892 shares during the last quarter. UBS Group AG grew its position in shares of Maximus by 76.8% in the 4th quarter. UBS Group AG now owns 610,354 shares of the health services provider’s stock valued at $52,686,000 after buying an additional 265,095 shares during the last quarter. Finally, Bank of America Corp DE grew its position in shares of Maximus by 24.6% in the 3rd quarter. Bank of America Corp DE now owns 453,616 shares of the health services provider’s stock valued at $41,447,000 after buying an additional 89,693 shares during the last quarter. Institutional investors own 97.21% of the company’s stock.

Insiders Place Their Bets

In related news, Director Jan Madsen sold 742 shares of the company’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $72.25, for a total transaction of $53,609.50. Following the transaction, the director directly owned 20,795 shares of the company’s stock, valued at approximately $1,502,438.75. This represents a 3.45% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.80% of the company’s stock.

Maximus Stock Down 0.1%

Shares of Maximus stock opened at $60.49 on Monday. Maximus, Inc. has a one year low of $56.92 and a one year high of $100.00. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.21 and a quick ratio of 2.21. The stock’s 50-day moving average is $63.79 and its 200 day moving average is $76.60. The firm has a market cap of $3.18 billion, a price-to-earnings ratio of 9.06 and a beta of 0.58.

Maximus (NYSE:MMS) last announced its earnings results on Thursday, May 7th. The health services provider reported $2.07 EPS for the quarter, beating the consensus estimate of $1.98 by $0.09. Maximus had a return on equity of 25.10% and a net margin of 7.02%.The company had revenue of $1.31 billion for the quarter, compared to analyst estimates of $1.32 billion. During the same quarter in the prior year, the company earned $2.01 EPS. The firm’s revenue for the quarter was down 4.1% compared to the same quarter last year. Maximus has set its FY 2026 guidance at 8.250-8.550 EPS. Equities research analysts anticipate that Maximus, Inc. will post 8.43 EPS for the current year.

Maximus Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, June 1st. Investors of record on Friday, May 15th were paid a dividend of $0.33 per share. This represents a $1.32 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date of this dividend was Friday, May 15th. Maximus’s dividend payout ratio is 19.76%.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Zacks Research lowered Maximus from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 27th. Wall Street Zen upgraded Maximus from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, Weiss Ratings lowered Maximus from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, May 20th. Two analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, Maximus presently has a consensus rating of “Hold”.

About Maximus

Maximus, Inc (NYSE: MMS) is a global provider of government services focused on delivering health and human services programs. The company partners with federal, state, and local agencies to administer and manage programs that support individuals and families across various stages of life. Key service areas include eligibility determination and enrollment services for Medicaid, Medicare, Children’s Health Insurance Program (CHIP) and other public assistance programs, as well as call center operations, case management and program integrity solutions.